G. Camboni

发表

Is PDGFR an important target for E-3810?

M. D’Incalci, G. Damia, G. Colella, 2012, Journal of cellular and molecular medicine.

Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test.

R. Penagini, D. Conte, P. Bianchi, 1985, Gut.

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

C. Gisselbrecht, P. Borchmann, J. Harousseau, 2003, Haematologica.

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

V. Diehl, A. Bernareggi, P. Staib, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

J. Smyth, D. Jodrell, A. Bernareggi, 2000, European journal of cancer.

Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1:

M. D’Incalci, G. Damia, G. Colella, 2011 .

A phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

P. Borchmann, J. Harousseau, R. Herbrecht, 2003 .

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer

D. Bisset, D. Jodrell, J. Cassidy, 2004, Cancer Chemotherapy and Pharmacology.

Lactose malabsorption and intolerance in Italians

R. Penagini, D. Conte, P. Bianchi, 1986, Digestive Diseases and Sciences.

Three months of octreotide treatment decreases gastric acid secretion and argyrophil cell density in patients with Zollinger‐Ellison syndrome and antral G‐cell hyperfunction

C. Bordi, V. Corleto, B. Annibale, 1994, Alimentary pharmacology & therapeutics.

Orocecal transit delay in obese patients

P. Bianchi, G. Basilisco, S. Doldi, 1989, Digestive Diseases and Sciences.

Loperamide and oro‐caecal transit delay [letter]

P. Bianchi, G. Basilisco, A. Bozzani, 1986 .

Loperamide and oro-caecal transit delay.

P. Bianchi, G. Basilisco, A. Bozzani, 1986, British journal of clinical pharmacology.

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

J. Carmichael, F. D. De Braud, D. Cameron, 2004, European journal of cancer.

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

M. Zucchetti, M. D’Incalci, G. Damia, 2012, Molecular Cancer Therapeutics.

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.

M. D’Incalci, G. Damia, G. Colella, 2011, Cancer research.

Oral naloxone antagonizes loperamide-induced delay of orocecal transit

G. Basilisco, P. Bianchi, A. Bozzani, 1987, Digestive Diseases and Sciences.

P-523 Phase II trial of BBR3464, a novel, bifunctional platinum analog, as second line treatment of non-small cell lung cancer patients

G. Scagliotti, S. Novello, L. Crinò, 2003 .

Lactose malabsorption and intolerance in Italians. Clinical implications.

R. Penagini, D. Conte, P. Bianchi, 1986, Digestive diseases and sciences.

A work in progress: The clinical development of histone deacetylase inhibitor

S. Marsoni, G. Damia, G. Camboni, 2008, Epigenetics.

Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer

H. Earl, M. Gore, C. Sessa, 2001 .

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.

M. Zucchetti, G. Grasselli, C. Sessa, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts

M. Zucchetti, M. D’Incalci, G. Damia, 2012, Molecular Cancer Therapeutics.

Plasma prolactin, sex steroids and gastrin in human volunteers treated for 2 weeks with therapeutic doses of cimetidine or the new histamine H2-receptor antagonist ramixotidine (CM 57755A)

E. Ruedas, L. Manara, M. Colle, 2004, European Journal of Clinical Pharmacology.

Repeatability of lactulose hydrogen breath test in subjects with normal or prolonged orocecal transit

G. Basilisco, P. Bianchi, A. Bozzani, 1988, Digestive Diseases and Sciences.

Intragastric and intraoesophagel pH monitoring in duodenal ulcer patients: effect of the new histamine H2-receptor antagonist ramixotidine

P. Bianchi, G. Basilisco, A. Bozzani, 2004, European Journal of Clinical Pharmacology.

A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

E. Raymond, J. Armand, S. Faivre, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath test.

R. Penagini, M. Recchia, G. Basilisco, 1985, Gut.